Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer

Edouard Auclin; Jose Benitez-Montanez; Marco Tagliamento; Francesca Parisi; Teresa Gorria; Rosario Garcia-Campelo; Naomi Dempsey; David J. Pinato; Roxana Reyes; Victor Albarran-Artahona; Filippo Dall'Olio; Davide Soldato; Lizza Hendriks; Frank Aboubakar Nana; Marion Tonneau; Rafael Lopez-Castro; Ernest Nadal; Suzanne Kazandjian; Thierry Muanza; Felix Blanc-Durand; Elizabeth Fabre; Natalia Castro; Hugo Arasanz; Adrien Rochand; Benjamin Besse; Bertrand Routy; Laura Mezquita

doi:10.1016/j.lungcan.2023.02.002

Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer

Edouard Auclin
, Jose Benitez-Montanez
, Marco Tagliamento
, Francesca Parisi
, Teresa Gorria
, Rosario Garcia-Campelo
, Naomi Dempsey
, David J. Pinato
, Roxana Reyes
, Victor Albarran-Artahona
, Filippo Dall'Olio
, Davide Soldato
, Lizza Hendriks
, Frank Aboubakar Nana
, Marion Tonneau
, Rafael Lopez-Castro
, Ernest Nadal
, Suzanne Kazandjian
, Thierry Muanza
, Felix Blanc-Durand

Elizabeth Fabre, Natalia Castro, Hugo Arasanz, Adrien Rochand, Benjamin Besse, Bertrand Routy^*, Laura Mezquita

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

338 Downloads (Pure)

Abstract

Introduction: Chemotherapy plus immunotherapy is the standard of care for patients with metastatic NSCLC. No study has evaluated the outcomes of second-line chemotherapy treatments after progression following first-line chemo-immunotherapy. Method: This multicenter retrospective study evaluated the efficacy of second line (2L) chemotherapies after progression under first-line (1L) chemo-immunotherapy, measured by overall survival (2L-OS) and progression free survival (2L-PFS). Results: A total of 124 patients were included. The mean age was 63.1 years, 30.6 % of the patients were female, 72.6 % had an adenocarcinoma and 43.5 % had a poor ECOG-performance status prior to 2L initiation. Sixty-four (52.0 %) patients were considered resistant to first line chemo-immunotherapy. (1L-PFS < 6 months). In 2L treatments, 57 (46.0 %) patients received taxane monotherapy, 25 (20.1 %) taxane plus anti-angiogenic, 12 (9.7 %) platinum-based chemotherapy and 30 (24.2 %) other chemotherapy.

Original language	English
Pages (from-to)	116-122
Number of pages	7
Journal	Lung Cancer
Volume	178
Issue number	1
DOIs	https://doi.org/10.1016/j.lungcan.2023.02.002
Publication status	Published - 1 Apr 2023

Keywords

Non small cell lung cancer
Chemo-immunotherapy
Second line
Prognosis
Survival
DOCETAXEL
NIVOLUMAB

Access to Document

10.1016/j.lungcan.2023.02.002

Full TextFinal published version, 2.53 MBLicence: Taverne

Cite this

Auclin, E., Benitez-Montanez, J., Tagliamento, M., Parisi, F., Gorria, T., Garcia-Campelo, R., Dempsey, N., Pinato, D. J., Reyes, R., Albarran-Artahona, V., Dall'Olio, F., Soldato, D., Hendriks, L., Nana, F. A., Tonneau, M., Lopez-Castro, R., Nadal, E., Kazandjian, S., Muanza, T., ... Mezquita, L. (2023). Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer. Lung Cancer, 178(1), 116-122. https://doi.org/10.1016/j.lungcan.2023.02.002

@article{2a3969fc39a94e77944475b5ef903d90,

title = "Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer",

abstract = "Introduction: Chemotherapy plus immunotherapy is the standard of care for patients with metastatic NSCLC. No study has evaluated the outcomes of second-line chemotherapy treatments after progression following first-line chemo-immunotherapy. Method: This multicenter retrospective study evaluated the efficacy of second line (2L) chemotherapies after progression under first-line (1L) chemo-immunotherapy, measured by overall survival (2L-OS) and progression free survival (2L-PFS). Results: A total of 124 patients were included. The mean age was 63.1 years, 30.6 \% of the patients were female, 72.6 \% had an adenocarcinoma and 43.5 \% had a poor ECOG-performance status prior to 2L initiation. Sixty-four (52.0 \%) patients were considered resistant to first line chemo-immunotherapy. (1L-PFS < 6 months). In 2L treatments, 57 (46.0 \%) patients received taxane monotherapy, 25 (20.1 \%) taxane plus anti-angiogenic, 12 (9.7 \%) platinum-based chemotherapy and 30 (24.2 \%) other chemotherapy.",

keywords = "Non small cell lung cancer, Chemo-immunotherapy, Second line, Prognosis, Survival, DOCETAXEL, NIVOLUMAB",

author = "Edouard Auclin and Jose Benitez-Montanez and Marco Tagliamento and Francesca Parisi and Teresa Gorria and Rosario Garcia-Campelo and Naomi Dempsey and Pinato, \{David J.\} and Roxana Reyes and Victor Albarran-Artahona and Filippo Dall'Olio and Davide Soldato and Lizza Hendriks and Nana, \{Frank Aboubakar\} and Marion Tonneau and Rafael Lopez-Castro and Ernest Nadal and Suzanne Kazandjian and Thierry Muanza and Felix Blanc-Durand and Elizabeth Fabre and Natalia Castro and Hugo Arasanz and Adrien Rochand and Benjamin Besse and Bertrand Routy and Laura Mezquita",

year = "2023",

month = apr,

day = "1",

doi = "10.1016/j.lungcan.2023.02.002",

language = "English",

volume = "178",

pages = "116--122",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

Auclin, E, Benitez-Montanez, J, Tagliamento, M, Parisi, F, Gorria, T, Garcia-Campelo, R, Dempsey, N, Pinato, DJ, Reyes, R, Albarran-Artahona, V, Dall'Olio, F, Soldato, D, Hendriks, L, Nana, FA, Tonneau, M, Lopez-Castro, R, Nadal, E, Kazandjian, S, Muanza, T, Blanc-Durand, F, Fabre, E, Castro, N, Arasanz, H, Rochand, A, Besse, B, Routy, B & Mezquita, L 2023, 'Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer', Lung Cancer, vol. 178, no. 1, pp. 116-122. https://doi.org/10.1016/j.lungcan.2023.02.002

TY - JOUR

T1 - Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer

AU - Auclin, Edouard

AU - Benitez-Montanez, Jose

AU - Tagliamento, Marco

AU - Parisi, Francesca

AU - Gorria, Teresa

AU - Garcia-Campelo, Rosario

AU - Dempsey, Naomi

AU - Pinato, David J.

AU - Reyes, Roxana

AU - Albarran-Artahona, Victor

AU - Dall'Olio, Filippo

AU - Soldato, Davide

AU - Hendriks, Lizza

AU - Nana, Frank Aboubakar

AU - Tonneau, Marion

AU - Lopez-Castro, Rafael

AU - Nadal, Ernest

AU - Kazandjian, Suzanne

AU - Muanza, Thierry

AU - Blanc-Durand, Felix

AU - Fabre, Elizabeth

AU - Castro, Natalia

AU - Arasanz, Hugo

AU - Rochand, Adrien

AU - Besse, Benjamin

AU - Routy, Bertrand

AU - Mezquita, Laura

PY - 2023/4/1

Y1 - 2023/4/1

N2 - Introduction: Chemotherapy plus immunotherapy is the standard of care for patients with metastatic NSCLC. No study has evaluated the outcomes of second-line chemotherapy treatments after progression following first-line chemo-immunotherapy. Method: This multicenter retrospective study evaluated the efficacy of second line (2L) chemotherapies after progression under first-line (1L) chemo-immunotherapy, measured by overall survival (2L-OS) and progression free survival (2L-PFS). Results: A total of 124 patients were included. The mean age was 63.1 years, 30.6 % of the patients were female, 72.6 % had an adenocarcinoma and 43.5 % had a poor ECOG-performance status prior to 2L initiation. Sixty-four (52.0 %) patients were considered resistant to first line chemo-immunotherapy. (1L-PFS < 6 months). In 2L treatments, 57 (46.0 %) patients received taxane monotherapy, 25 (20.1 %) taxane plus anti-angiogenic, 12 (9.7 %) platinum-based chemotherapy and 30 (24.2 %) other chemotherapy.

AB - Introduction: Chemotherapy plus immunotherapy is the standard of care for patients with metastatic NSCLC. No study has evaluated the outcomes of second-line chemotherapy treatments after progression following first-line chemo-immunotherapy. Method: This multicenter retrospective study evaluated the efficacy of second line (2L) chemotherapies after progression under first-line (1L) chemo-immunotherapy, measured by overall survival (2L-OS) and progression free survival (2L-PFS). Results: A total of 124 patients were included. The mean age was 63.1 years, 30.6 % of the patients were female, 72.6 % had an adenocarcinoma and 43.5 % had a poor ECOG-performance status prior to 2L initiation. Sixty-four (52.0 %) patients were considered resistant to first line chemo-immunotherapy. (1L-PFS < 6 months). In 2L treatments, 57 (46.0 %) patients received taxane monotherapy, 25 (20.1 %) taxane plus anti-angiogenic, 12 (9.7 %) platinum-based chemotherapy and 30 (24.2 %) other chemotherapy.

KW - Non small cell lung cancer

KW - Chemo-immunotherapy

KW - Second line

KW - Prognosis

KW - Survival

KW - DOCETAXEL

KW - NIVOLUMAB

U2 - 10.1016/j.lungcan.2023.02.002

DO - 10.1016/j.lungcan.2023.02.002

M3 - Article

C2 - 36812760

SN - 0169-5002

VL - 178

SP - 116

EP - 122

JO - Lung Cancer

JF - Lung Cancer

IS - 1

ER -

Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this